EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Risk of therapy related leukemia and preleukemia after hodgkin's disease relation to age cumulative dose of alkylating agents and time from chemotherapy






Lancet 2(8550): 83-88

Risk of therapy related leukemia and preleukemia after hodgkin's disease relation to age cumulative dose of alkylating agents and time from chemotherapy

391 patients treated intensively for Hodgkin's disease were followed for up to 15 years to evaluate the risk of therapy-related acute non-lymphocytic leukaemia (t-ANLL) and preleukaemia. Only two independent factors, patient age and cumulative dose of alkylating agents, were related to the risk of t-ANLL. The hazard rate of t-ANLL was roughly proportional to the square of patients age and to the total cumulative dose of alkylating agents. In 320 patients treated with alkylating agents the cumulative risk of t-ANLL increased steadily from 1 year after the start of treatment and reached 13.cntdot.0% (SE 3.cntdot.0) at 10 years after which time there were no further cases. Calculated from cessation of therapy with alkylating agents, however, the cumulative risk curve increased steeply during the first 1-2 years then gradually levelled out and no new cases were observed beyond 7 years. With a 15-year follow-up the general risk of solid tumours was not increased.


Accession: 006345707

PMID: 2885581



Related references

Pedersen-Bjergaard, J.; Specht, L.; Larsen, S.O.; Ersbøll, J.; Struck, J.; Hansen, M.M.; Hansen, H.H.; Nissen, N.I., 1987: Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. 391 patients treated intensively for Hodgkin's disease were followed for up to 15 years to evaluate the risk of therapy-related acute non-lymphocytic leukaemia (t-ANLL) and preleukaemia. Only two independent factors, patient age and cumulativ...

van Leeuwen, F.E.; Chorus, A.M.; van den Belt-Dusebout, A.W.; Hagenbeek, A.; Noyon, R.; van Kerkhoff, E.H.; Pinedo, H.M.; Somers, R., 1994: Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. Purpose The development of leukemia is one of the most serious long-term complications of modern treatment for Hodgkin's disease (HD). This study was undertaken to examine the relation between risk of leukemia and various treatment factors (i...

Pedersen-Bjergaard, J.; Ersbøll, J.; Sørensen, H.M.; Keiding, N.; Larsen, S.O.; Philip, P.; Larsen, M.S.; Schultz, H.; Nissen, N.I., 1985: Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow. A Kaplan-Meier estimate of the cumulative probabil...

Pedersen-Bjergaard, J.; Janssen, W.G.; Lyons, J.; Philip, P.; Bartram, C.R., 1988: Point mutation of the ras protooncogenes and chromosome aberrations in acute nonlymphocytic leukemia and preleukemia related to therapy with alkylating agents. Nine cases of overt acute nonlymphocytic leukemia and four cases of preleukemia or a myelodysplastic syndrome, all related to intensive treatment with alkylating agents, were studied cytogenetically and investigated using a rapid and sensitive dot...

Appelbaum F.R.; Storb R.; Buckner C.D.; Ramberg R.E.; Shulman H.M.; Sargur M.; Clift R.A.; Deeg H.J.; Fefer A.; E.A., 1987: The role of marrow transplantation in the treatment of preleukemia therapy related preleukemia and acute leukemia evolving from preleukemia. Gale, R P And R Champlin (Ed ) Ucla (University Of California-Los Angeles) Symposia on Molecular And Cellular Biology New Series, Vol 53 Progress in Bone Marrow Transplantation; Fourth International Symposium, Keystone, Colorado, Usa, April 13-18, 1986 Xxxv+1012p Alan R Liss, Inc : New York, New York, Usa Illus 103-120

Lee, J.L.; Gooley, T.; Bensinger, W.; Schiffman, K.; Mcdonald, G.B., 1997: Venocclusive disease of the liver after high-dose chemotherapy with alkylating agents Incidence, outcome, and risk factors. Hepatology 26(4 PART 2): 149A

Pedersen Bjergaard J.; Ersboll J.; Sorensen H.M.; Keiding N.; Larsen S.O.; Philip P.; Larsen M.S.; Schultz H.; Nissen N.I., 1985: Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non hodgkins lymphomas comparison with results obtained in patients treated for hodgkins disease and ovarian carcinoma with other alkylating agents. Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow. A Kaplan-Meier estimate of the cumulative probabil...

Pedersen Bjergaard J., 1990: Risk of therapy related myelodysplasia acute non lymphocytic leukemia and bladder cancer following therapy with alkylating agents the finsen institute denmark experience. Journal of Cancer Research & Clinical Oncology 116(SUPPL PART 2): 983

Henry-Amar, M.; Pellae-Cosset, B.; Bayle-Weisgerber, C.; Hayat, M.; Cosset, J.M.; Carde, P.; Tubiana, M., 1989: Risk of secondary acute leukemia and preleukemia after Hodgkin's disease: the Institut Gustave-Roussy experience. From 1960 to 1984, 871 patients were treated for Hodgkin's disease at the Institut Gustave-Roussy. Twenty-six percent of the cohort were treated with radiotherapy (RT) alone, 6% with chemotherapy (CT) alone, and 68% with a combination of RT a...

Dann, E.J.; Bar-Shalom, R.; Tamir, A.; Haim, N.; Ben-Shachar, M.; Avivi, I.; Zuckerman, T.; Kirschbaum, M.; Goor, O.; Libster, D.; Rowe, J.M.; Epelbaum, R., 2006: Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Therapy of Hodgkin disease (HD) is designed to prolong progression-free survival and minimize toxicity. The best regimen to achieve this has not yet been defined. A total of 108 patients with newly diagnosed HD and adverse prognostic factors were...